Compare · CV vs SLNO
CV vs SLNO
Side-by-side comparison of CapsoVision Inc. (CV) and Soleno Therapeutics Inc. (SLNO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CV and SLNO operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- SLNO is the larger of the two at $2.76B, about 8.1x CV ($342.3M).
- Over the past year, CV is up 69.7% and SLNO is down 31.5% - CV leads by 101.2 points.
- SLNO has been more active in the news (42 items in the past 4 weeks vs 6 for CV).
- SLNO has more recent analyst coverage (12 ratings vs 2 for CV).
- Company
- CapsoVision Inc.
- Soleno Therapeutics Inc.
- Price
- $6.80-1.80%
- $53.02+0.08%
- Market cap
- $342.3M
- $2.76B
- 1M return
- -3.75%
- +0.76%
- 1Y return
- +69.70%
- -31.50%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2025
- 2014
- News (4w)
- 6
- 42
- Recent ratings
- 2
- 12
Soleno Therapeutics Inc.
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release (DCCR), a once-daily oral tablet for the treatment of Prader-Willi Syndrome (PWS), is being evaluated in a Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics has collaboration with Vanderbilt University to discover and develop next generation K(ATP) channel activators for the treatment of rare diseases. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California.
Latest CV
- SEC Form 4 filed by Officer Wang Kang-Huai
- SEC Form 4 filed by Sr. VP of Finance Garcia David Michael
- SEC Form 4 filed by Head of Global Sales Atkinson Douglas Patrick
- SEC Form 10-Q filed by CapsoVision Inc.
- CapsoVision Inc. filed SEC Form 8-K: Results of Operations and Financial Condition
- CapsoVision Reports First Quarter 2026 Financial Results
- Amendment: SEC Form SCHEDULE 13G/A filed by CapsoVision Inc.
- Head of Global Sales Atkinson Douglas Patrick exercised 107,357 shares at a strike of $0.42 (SEC Form 4)
- CapsoVision to Release First Quarter 2026 Financial Results on May 14, 2026
- SEC Form DEF 14A filed by CapsoVision Inc.
Latest SLNO
- SEC Form 15-12G filed by Soleno Therapeutics Inc.
- SEC Form EFFECT filed by Soleno Therapeutics Inc.
- SEC Form POS AM filed by Soleno Therapeutics Inc.
- SEC Form AW filed by Soleno Therapeutics Inc.
- Officer Yen Kristen returned 37,639 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Volck Birgitte returned 17,536 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Sinclair Andrew returned 10,491 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Pauls Matthew returned 10,491 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Chief Business Officer Norrett Kevin returned 17,786 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Chief Commercial Officer Manning Meredith returned 64,507 shares to the company, closing all direct ownership in the company (SEC Form 4)